Toxin-induced coagulopathy

Area of Science:

• Pharmacology
• Hematology
• Internal Medicine

Background:

• Warfarin and heparin have been primary anticoagulants for decades.
• Recent advancements introduced novel oral anticoagulants (NOACs).
• NOACs target specific clotting factors, offering alternatives to traditional therapies.

Purpose of the Study:

• To review the shift in anticoagulant choice from warfarin to newer agents.
• To highlight the advantages of direct thrombin and factor Xa inhibitors.
• To discuss the implications for patient management and adherence.

Main Methods:

• Literature review of anticoagulant therapies.
• Analysis of clinical data on warfarin, heparin, and NOACs.
• Comparison of efficacy, safety, and monitoring requirements.

Main Results:

• NOACs, including direct thrombin and factor Xa inhibitors, are increasingly preferred.
• These agents offer oral administration and targeted action.
• Elimination of routine blood monitoring simplifies patient management.

Conclusions:

• Novel oral anticoagulants represent a significant advancement in anticoagulation therapy.
• Their targeted specificity and oral bioavailability enhance patient convenience.
• These drugs are becoming the preferred choice for managing various thromboembolic conditions.